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Background: Cystatin C (CysC) is an endogenous cysteine protease inhibitor that can be used to assess the
progression of kidney function. Recent studies demonstrate that CysC is a more specific indicator of glomerular
filtration rate (GFR) than creatinine. CysC in plasma exists in multiple proteoforms. The goal of this study was to
clarify the association of native CysC, CysC missing N-terminal Serine (CysC des-S), and CysC without three
N-terminal residues (CysC des-SSP) with diabetic chronic kidney disease (CKD).
Results: Using mass spectrometric immunoassay, the plasma concentrations of native CysC and the two CysC
truncation proteoforms were examined in 111 individuals from three groups: 33 non-diabetic controls, 34
participants with type 2 diabetes (DM) and without CKD and 44 participants with diabetic CKD. Native CysC
concentrations were 1.4 fold greater in CKD compared to DM group (p = 0.02) and 1.5 fold greater in CKD
compared to the control group (p = 0.001). CysC des-S concentrations were 1.55 fold greater in CKD compared to
the DM group (p = 0.002) and 1.9 fold greater in CKD compared to the control group (p = 0.0002). CysC des-SSP
concentrations were 1.8 fold greater in CKD compared to the DM group (p = 0.008) and 1.52 fold greater in CKD
compared to the control group (p = 0.002). In addition, the concentrations of CysC proteoforms were greater in the
setting of albuminuria. The truncated CysC proteoform concentrations were associated with estimated GFR
independent of native CysC concentrations.
Conclusion: Our findings demonstrate a greater amount of CysC proteoforms in diabetic CKD. We therefore
suggest assessing the role of cystatin C proteoforms in the progression of CKD.
Keywords: Cystatin C, Truncations, Mass spectrometry, Chronic kidney diseaseBackground
Cystatin C (CysC) is a cysteine proteinase inhibitor
belonging to the type 2 cystatin gene family [1–3]. It is a
non-glycosylated single chain protein with a molecular
weight of 13,343 Da. CysC is produced at a constant rate
by nucleated cells, and is freely filtered by the renal
glomerulus, therefore, has been used to monitor the
progression of chronic kidney disease (CKD) [4].
CKD is defined by a decline of glomerular filtration
rate (GFR) to <90 mL/min/1.73 m2 and by the presence* Correspondence: dobrin.nedelkov@asu.edu
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affects 26 million American adults, while millions of
others are at increased risk. In clinical practice,
estimated GFR (eGFR) is used to evaluate CKD and
categorize the disease into different stages (1–5) based
on severity. GFR is defined as the volume of plasma that
can be completely cleared of a particular substance by
the kidneys in a unit of time [7]. Accurate diagnosis and
staging of CKD is critical for therapy and clinical
implications.
Currently, serum creatinine is used to calculate eGFR.
However, eGFR determined by creatinine-based equations
can be biased by several factors that are not related to
kidney function including age, race, sex, muscle mass,is distributed under the terms of the Creative Commons Attribution 4.0
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levels. In a recent study by Stevens et al., creatinine-based
estimates of GFR could not accurately detect acute
changes in kidney function [8]. In addition, 5 – 10 % of
excreted creatinine originates from distal tubule secretion.
This excretion increases in response to decreased GFR,
making it difficult to accurately detect small to moderate
changes in GFR [2]. Therapies that block distal tubule
secretion of creatinine (e.g., trimethoprim, cimetidine,
cefoxitin) can also increase serum creatinine levels, and
alter the GFR estimation [9].
In a meta-analysis by Shlipak, et al. [10], reclassification
of kidney function with CysC improved the prediction of
cardiovascular and renal morbidity and mortality.
Additionally, in experimental mice models of acute renal
failure, CysC was a more sensitive measure of renal insuf-
ficiency after bilateral nephrectomy compared to serum
creatinine [11]. In a study by Coll et al. [12], serum
creatinine levels increased in 92.15 % of patients with
impaired renal function compared to serum CysC levels
which was increased in 100 % of patients. CysC started
increasing at eGFR value of 88 mL/min/1.73 m2, while
creatinine levels increased at eGFR of 75 mL/min/
1.73 m2. Furthermore, the study showed that only CysC
levels were significantly elevated in hypertensive
patients with no evidence of renal failure and minimal
proteinuria [12].
CysC undergoes posttranslational modifications in the
plasma to form multiple proteoforms [13]. Protein modi-
fications play important roles in biological processes,
and can serve as diagnostic indicators of pathological
events. Mass spectrometric immunoassay (MSIA) is a
high throughput assay well suited to identify and quan-
tify molecular variants and posttranslational modifica-
tions of plasma proteins [14, 15]. MSIA involves the
isolation of protein moieties from a biological milieu by
immobilized antibodies, followed by mass spectrometric
detection. We recently reported in a population of 500
healthy adults 3 posttranslationally modified CysC
proteoforms: one containing hydroxyproline, and 2
truncated proteoforms; one missing N-terminal serine,
and one lacking three N-terminal residues [13]. The
distribution of CysC proteoforms in CKD is not known.
In the present study, we investigate the CysC truncations
in non-diabetic controls and patients with DM and CKD
using MSIA.
Methods
Clinical samples
The study was approved by the University of Arizona
Institutional Review Board, and written informed
consent was obtained from all patients. Three groups of
adult participants were recruited: 33 participants without
CKD and without DM (control), 34 participants withoutCKD and with DM (DM group), and 44 participants
with both CKD and DM (CKD group). Participants
reported to the Center for Clinical and Translational
Sciences after an overnight fast. Blood was collected for
clinical laboratory measurements (lipid profile, Hemoglobin
A1C (HbA1C), C-reactive protein (CRP), and fasting
insulin). Additional samples were collected in EDTA
tubes, and plasma from these samples was separated
and immediately frozen at −80 °C for all other assays.
Demographic information (age, sex, ethnicity), physical
exam measurements (blood pressure, waist circumference,
weight, height, body mass index (BMI)), medication use,
and medical history (hypertension, hyperlipidemia, smok-
ing, type and duration of diabetes) were also recorded.
GFR was estimated using the Modification of Diet in
Renal Disease Study (MDRD) equation. Assignment of
CKD (stages 1–5) was based on eGFR levels as described
[16]. Exclusion criteria included the following: type 1
diabetes, participation in an active weight loss program,
pregnancy, dysuria, thyroid dysfunction, history of cancer,
HIV, active infection, other ongoing serious illness or
current steroid use. Diabetes classification was based on
clinical and medication history, or glycated hemoglobin
greater than 6 %.
Reagents
Polyclonal goat anti-human CysC antibody (Cat. No.
GCYS-80A) was obtained from ICLLab (Portland, OR).
Affinity purified rabbit anti-bovine beta lactoglobulin
antibody (Cat. No. GTX77272) was purchased from
GeneTex (Irvine, CA). Native human CysC (Cat. No
CRC173B) was obtained from Cell Sciences (Canton,
MA). Protein calibration standard I (Cat. No. 206355)
was purchased from Bruker (Billerica, MA). Phosphate
buffered saline (PBS) buffer (Cat. No. 28372), MES
buffered saline (28390), 1, 1’carbonyldiimidazole (97 %)
(CDI, 530-62-1), acetonitrile (ACN, A955-4), hydro-
chloric acid (HCl, A144-212), N-Methylpyrrolidinone
(NMP, BP1172-4) and affinity pipettes fitted with porous
microcolumns (991CUS01) were obtained from Thermo
Scientific (Waltham, MA, USA). Beta lactoglobulin (BL)
from bovine milk (Cat. No. L8005), Tween 20 (Cat. No.
P7949), trifluoroacetic acid (TFA, 299537-100G), sinapic
acid (85429-5G), sodium chloride (S7653), HEPES
(H3375), ethanolamine (ETA, 398136) and albumin from
bovine serum (BSA, A7906), were obtained from Sigma
Aldrich (St. Louis, MO, USA). Acetone (Cat. No.
0000017150) was obtained from Avantor Performance
Materials (Center Valley, PA, USA).
Analytical samples preparation
Frozen plasma samples were briefly thawed on ice,
centrifuged at 3000 rpm for 5 min, and 50 μL aliquots
were placed into low profile 96-well trays. To generate
Fig. 1 MALDI-MSIA-mass spectra showing all CysC proteoforms.
Signals for native CysC along with several cystatin C proteoforms:
CysC containing hydroxyproline at position 3 (CysC 3Pro-OH), CysC
missing its N-terminal Serine (CysC des-S), and CysC missing its three
N-terminal residues (CysC des-SSP) are detected. BL is beta lactoglobulin
used as an internal reference standard for quantification
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PBS buffer containing 3 g/L BSA, to final concentrations
of 1.25 mg/L (standard 1), 0.625 mg/L (standard 2),
0.313 mg/L (standard 3), 0.156 mg/L (standard 4),
0.078 mg/L (standard 5) and 0.039 mg/L (standard 6).
Beta lactoglobulin (BL) was used as an internal reference
standard (IRS) for quantification, and was prepared in
water, to a final concentration of 1 mg/mL. Human
plasma samples were diluted 5-times in PBS, 0.1 % Tween
prior to analysis. The analytical samples were prepared by
combining 20 μL of the CysC standard solution or the di-
luted plasma with 40 μL of a 1 mg/mL solution of BL, and
100 μL PBS 0.1 % Tween buffer.
Mass spectrometric immunoassay
Affinity pipettes derivatization and assay execution was
done on a Multimek 96-channel pipettor (Beckman
Coulter, Brea, CA) as previously described [17] . Initially,
affinity pipettes were derivatized with antibodies towards
CysC (the targeted protein) and BL (the internal reference
standard) in a ratio of 4.5:1 (w/w; CysC:BL, 3.6 μg
anti-CysC, 50 μL/well), as described previously in the
protocol [13, 17]. Antibody-derivatized pipettes were
stored at +4 °C until used. Prior to sample protein
extraction, the derivatized affinity pipettes were pre-
rinsed with assay buffer (PBS, 0.1 % Tween, 10 aspir-
ation/dispense cycles, 100 μL each). Pipettes were
then immersed into a microplate containing analytical
samples, and 250 aspirations/dispense cycles were
performed (100 μL each) allowing for optimal affinity
capture of both CysC and BL. The pipettes were then
rinsed with PBS 0.1 % Tween (100 cycles, 100 μL
aspiration/dispense volumes), and twice with water
(10 cycles and 20 cycles respectively, 100 μL aspir-
ation/dispense each). Protein-loaded tips were then
exposed to six-microliter aliquots of MALDI matrix
solution (25 g/L sinapic acid in aqueous solution
containing 33 % (v/v) acetonitrile, and 0.4 % (v/v)
trifluoroacetic acid). After a 10 s delay (to allow for
the dissociation of the protein from the capturing
antibody), the eluates were dispensed directly onto a
96-well formatted MALDI target. After samples were
dried, linear-mode mass spectra was acquired from
each sample spot, each consisting of ten thousand
laser shots using an Autoflex III MALDI-TOF mass
spectrometer (Bruker, Billerica, MA). For accurate
mass assignment, the mass spectra were externally
calibrated with protein standard I (Cat. No. 8206355,
Bruker, Billerica, MA) and also with the internal
reference standard (mass accuracy up to 0.001 Da). In
addition, the mass spectra were baseline subtracted
(Tophat algorithm) and smoothed (SavitzkyGolay
algorithm; width = 0.2 m/z; cycles = 1), before peak
integration with Flex Analysis 3.0 software (BrukerDaltonics). Peak areas for all CysC signals and BL were
measured in Zebra software (Beavis Informatics, Ltd.).
The hydroxylated proteoforms were not baseline-resolved
from their corresponding proteoforms and were therefore
co-integrated with their originating proteoforms.
Quantitative MSIA analysis of CysC proteoforms
Quantification of CysC was done as previously described
[17] . In short, standard curve was generated, utilizing
the corresponding protein standard (CysC) and the
internal reference standard (BL). Separate standard
curves were created with each run, by plotting the ratio
of the peak areas of the CysC standard signal and the BL
signal (CysC/BL) against CysC standard concentration
(c(CysC)). The linear equations obtained were used to
calculate the concentrations of native CysC and CysC
proteoforms in the analyzed samples, using the ratio of
the peak areas of each proteoform to the IRS. Peak area
ratios for each CysC proteoforms against BL were
summed up, and, total CysC concentration was deter-
mined using the standard curve equation. Individual
CysC proteoform concentrations were calculated using
the percent abundance in correspondence to total CysC.
The reproducibility of the assay was tested by analyzing
a control sample with known CysC concentration in
triplicates with each run. This control sample was used
to assess the within and between run variability. MSIA
can identify total of 5 CysC proteoforms (Fig. 1). How-
ever, due to the inability to be resolved at a baseline
level, CysC hydroxylated proteoforms were integrated
with their originating proteoforms. An example of a
standard curve, together with the corresponding mass
spectra is presented in Additional file 1: Figure S1. The
control sample run in triplicates showed within-run
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concentrations of the three major CysC proteoforms
were analyzed in plasma of all participants using MSIA.
Statistical analysis
Mean (SD) and median (25th and 75th percentiles) were
used to describe normally and non-normally distributed
continuous variables, respectively. The control, DM and
CKD groups were compared using one-way ANOVA
(normally distributed variables) or Kruskal-Wallis test
(non-normally distributed variables). Categorical variables
were compared using chi-square test. Linear regression
was used to analyze the association of GFR with CysC
proteoforms. All regression models were adjusted for age,
sex, and BMI as covariates. Partial correlation was used to
test independent correlation of native CysC, CysC des-
SSP and CysC des-S with eGFR. All statistical analyses
were performed using SAS version 9.4 software package.Table 1 Demographic, clinical and biochemical characteristics of stu
Characteristic N1/N2/N3 Control
Age, years 33/34/44 43.82 (14.9
Sex 33/34/44
Male 15 (45.45
Female 12 (70.59)
Race 33/34/44
Caucasians 24 (72.73
Hispanics 8 (24.24 %
Others 1 (3.03 %)
Body mass index, kg/m2 33/34/40 24.37 (3.25
Waist circumference, cm 32/33/35 86.94 (12.0
Glucose, mg/dL 33/34/37 98 (88, 10
Hemoglobin A1C, % 33/31/40 5.2 (4.9, 5.
LDL cholesterol, mg/dL 33/34/41 118.09 (31
HDL cholesterol, mg/dL 33/34/41 54.97 (16.4
Total cholesterol, mg/dL 33/34/41 198.12 (41
Triglycerides, mg/dL 33/34/41 128 (96, 18
Fasting Insulin, IU 32/23/25 9.53 (7.68)
Urine Microalbumin, mg/mg creatinine 33/33/38 5 (5, 9)
CRP, mg/dL 16/24/33 1.24 (0.35,
Serum creatinine, mg/dL 33/34/44 0.6 (0.6, 0.
eGFR, mL/min/1.73 m2 33/34/44 120.66 (24
Mean (SD) or median (25th percentile, 75th percentile) shown for continuous variab
(percentage) shown for categorical variables. Statistical significance defined with a
Group categorization: control group defined as non-diabetic patients with eGFR ≥ 90 m
1.73 m2 and CKD group defined as diabetic patients with eGFR < 90 mL/min/1.73 m2
N1 = Control
N2 = DM
N3 = CKD
aCKD statistically different than DM and control
bDM statistically different than control
cControl statistically different than DM and CKD
dControl statistically different than CKDFor Cystatin C proteoforms, the alpha level was set at 0.02
adjusting for multiple comparisons. For the other
variables, the alpha level was set at 0.05.
Results
The demographic and clinical characteristics of individuals
in the control, DM and CKD groups are summarized in
Table 1. Participants in the CKD group were significantly
older than both the control and DM groups (p < 0.001).
The DM and CKD groups had elevated BMI (p < 0.001),
HbA1C (p < 0.001) and CRP (p < 0.001), as well as
decreased levels of HDL cholesterol (p < 0.01) compared
to controls. As expected, urine microalbumin and serum
creatinine were significantly greater, and eGFR was
lower in the CKD group compared to the two other
groups (p < 0.001).
Using mass spectrometric immunoassay we were able to
identify several CysC proteoforms (Table 2). An exampledy participants
DM CKD p-value
3) 51.97 (11.77) 61.09 (11.79) <0.001a,b
0.64
%) 17 (50 %) 25 (56.82)
17 (50 %) 19 (43.18)
0.25
%) 19 (55.88 %) 25 (56.82 %)
) 15 (44.12 %) 16 (36.36 %)
0 (0 %) 3 (6.82 %)
) 36.33 (10.26) 34.08 (8.28) <0.001c
7) 116.52 (20.82) 115.57 (18.95) <0.001c
7) 144 (123, 182) 142 (114, 202) <0.001c
4) 7.5 (6.7, 9.7) 7.6 (6.4, 9.3) <0.001c
.93) 111.09 (39.15) 101.95 (36.98) 0.16
1) 46.41 (11.60) 43.95 (13.29) <0.01c
.58) 191.15 (55.56) 182.15 (43.62) 0.35
2) 162 (124, 258) 166 (135,268) 0.02d
17.74 (11.32) 16.76 (13.02) 0.01c
11 (5, 27) 25 (9, 174) <0.001c
3.77) 6.80 (2.50, 12.43) 7.29 (3.91, 7.29) <0.001c
8) 0.7 (0.6, 0.9) 1.25 (1.00, 1.90) <0.001a
.09) 111.13 (25.90) 54.74 (24.97) <0.001a
les (normally distributed or non-normally distributed, respectively). Frequency
p < 0.05. IU: International Unit. eGFR: estimated glomerular filtration rate
L/min/1.73 m2, DM group defined as diabetic patients with eGFR≥ 90 mL/min/
Table 2 Cystatin C proteoforms detected by MSIA
Theoretical m/z Observed m/z Proteoform Label
13,071.833 13,072.684 Cystatin C lacking N-terminal tripeptide (SSP-) des-SSP CysC
13,256.027 13,256.897 Cystatin C lacking one N-terminal serine residue (S-) des-S CysC
13,272.027 13,272.649 Hydroxylated cystatin C (on 3-Pro residue) lacking N-terminal S-residuea des-S 3Pro-OH CysC
13,343.105 13,344.169 Full length, unmodified cystatin C native CysC
13,359.105 13,359.246 Hydroxylated cystatin C in position 3 on proline (Pro) residuea 3Pro-OH CysC
18,276.162 18,276.500 Beta lactoglobulin (internal reference standard) BL
CysC exists in multiple forms. The three main CysC variants are one containing hydroxyproline and 2 truncated variants; one missing N-terminal serine, and one
lacking three N-terminal residues. MSIA: Mass Spectrometric Immunoassay. BL: Beta lactoglobulin is the internal standard
aThe hydroxylated variants were co-integrated with their originating proteoforms, therefore were not individually correlated with the clinical parameters
Fig. 2 Distribution of CysC proteoforms concentrations across CKD stages in diabetic patients with and without CKD. There are 5 CKD stages
based on estimated GFR. Stage 1 is define by eGFR≥ 90 mL/min/1.73 m2 (n = 34), stage 2 is defined by 60≤ eGFR≤ 89 mL/min/1.73 m2 (n = 21),
stage 3a is defined by 45 ≤ eGFR≤ 59 mL/min/1.73 m2 (n = 6), stage 3b is defined 30≤ eGFR≤ 44 mL/min/1.73 m2 (n = 7), stage 4 is defined by
15≤ eGFR≤ 29 mL/min/1.73 m2 (n = 7), and stage 5 is defined by eGFR < 15 mL/min/1.73 m2 (n = 3). All CysC proteoforms significantly increased
across the advanced CKD stages (group ANOVA test). Using pairwise comparisons, des-SSP: stages 1-3b, 1–5, 1–4, 2-3b, 2–4, 2–5; des-S: stages
1–4, 1–5, 2–4, 3a-4; native: stages 1–5 and 1–4 were statistically different. These data suggest that des-SSP and des-S CysC proteoforms increase
more robustly by CKD stage compared with native CysC concentrations
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trol participant is shown in Fig. 1. Native CysC (represent-
ing sum of native and 3Pro-OH CysC), CysC-des-S (sum
of des-S CysC and des-S 3Pro-OH CysC), and CysC-des-
SSP concentrations were greater in participants with CKD
compared to participants without CKD (38–77 % greater
CysC proteoform concentrations, p < 0.01). Greater in-
creases in truncated CysC were observed across the differ-
ent CKD stages compared to native CysC concentrations
(Fig. 2). The distribution of CysC proteoforms across the
three groups is summarized in Table 3. Native CysC
concentrations were 1.4 fold greater in CKD compared to
DM group (p = 0.02) and 1.5 fold greater in CKD
compared to the control group (p = 0.001). CysC des-S
concentrations were 1.55 fold greater in CKD compared
to the DM group (p = 0.002) and 1.9 fold greater in CKD
compared to the control group (p = 0.0002). CysC des-SSP
concentrations were 1.8 fold greater in CKD compared to
the DM group (p = 0.008) and 1.52 fold greater in CKD
compared to the control group (p = 0.002).
To understand the relation of CysC proteoforms with
CKD, the concentrations of these proteoforms were
correlated with eGFR. Increases in CysC proteoforms
were negatively correlated with eGFR. This linear associ-
ation between CysC proteoform concentrations and
eGFR was significant after adjusting for age, sex and
BMI, as summarized in Table 4. However, subgroup ana-
lysis indicated that this association of CysC proteoforms
and eGFR was driven by the CKD group.
The concentrations of truncated proteoforms of CysC
had a stronger correlation with eGFR than native CysC
proteoform. The regression coefficients explaining the
correlation between CysC proteoforms and eGFR were
larger for truncated CysC proteoforms than the native
CysC proteoform. The truncated CysC proteoforms
correlated with eGFR independent of the native CysC.Table 3 Distribution of CysC proteoforms concentrations by DM an
N1/N2/N3 Control
Native CysC (mg/L) 33/34/44 1.09 (0.71,1.35)
CysC des-S (mg/L) 33/34/44 0.03 (0.025,0.046)
CysC des-SSP (mg/L) 33/34/44 0.06 (0.04,0.09)
Median (25th percentile, 75th percentile). Statistical significance defined with a p <
N1 = Control
N2 = DM
N3 = CKD
aNative CysC
In DM vs. controls, p = 0.6
In CKD vs. DM, p = 0.02
In CKD vs. controls, p = 0.001
bCysC des-S
In DM vs. controls, p = 0.8
In CKD vs. DM, p = 0.002
In CKD vs. controls, p = 0.0002
cCysC des-SSP
In DM vs. controls, p = 0.9
In CKD vs. DM, p = 0.008
In CKD vs. controls, p = 0.002The partial correlation of native CysC and CysC
truncations with eGFR demonstrated a significant
inverse correlation between CysC des- SSP and CysC
des-S concentrations and eGFR (r = −0.28, p = 0.003,
and r = −0.24, p = 0.01, respectively). The partial
correlation of native CysC with eGFR was not signifi-
cant (r = 0.15, p = 0.12). Therefore, truncated CysC
proteoforms were associated with eGFR independent of
native CysC; highlighting the importance for measuring
the truncated proteoforms in CKD patients.
To examine the relation of CysC truncations with
albuminuria, the distribution of CysC proteoforms was
analyzed in the combined sample (n = 104) where urine
microalbumin was measured. The three categories of
albuminuria were defined as no albuminuria (urine
microalbumin < 30 mcg/mg creatinine), micoalbuminuria
(urine microalbumin 30–300 mcg/mg creatinine) and
macroalbuminuria (urine microalbumin > 300 mcg/mg
creatinine). Eight patients had clinical albuminuria, 18 pa-
tients had micoalbuminuria, and 78 participants presented
with no evidence of albuminuria. Participants with
albuminuria had greater amounts of plasma CysC
proteoforms (p < 0.05) compared to participants with
normal albuminuria (Table 5). CysC des-SSP concen-
trations in the macroalbuminuria group were 1.57
fold greater compared to the normoalbuminuria
group (p = 0.02). CysC des-S concentrations in the
macroalbuminuria group were 1.56 fold greater com-
pared to the normoalbuminuria group (p = 0.05).
Discussion
Our findings demonstrate that CysC proteoforms are
greater in concentrations in participants in the CKD +
DM group compared to the DM and control groups.
Native CysC and CysC truncations (CysC des-SSP and
CysC des-S) were inversely correlated with eGFR andd CKD groups
DM CKD p-value
1.15(0.97,1.48) 1.59 (1.07, 2.02) <0.01a
0.039 (0.03,0.05) 0.059 (0.035,0.08) <0.01b
0.053 (0.02, 0.071) 0.094(0.035, 0.14) <0.01c
0.02. Groups compared with ANOVA followed by Tukey’s pairwise comparisons
Table 4 Association of CysC concentrations with eGFR
Combined sample Control DM CKD
N/N1/N2/N3 Regression
coefficient
Beta (SE)
P-value Regression
coefficient
Beta (SE)
P-value Regression
coefficient
Beta (SE)
P-value Regression
coefficient
Beta (SE)
P-value
Total CysC 107/33/34/40 −16.40 (17.62) <0.0001 2.47 (10.82) 0.82 −4.96 (7.66) 0.52 −10.09 (3.36) <0.01
CysC des-SSP 107/33/34/40 −245.96 (44.41) <0.0001 −83.46 (106.80) 0.44 −132.88 (116.49) 0.26 −177.17 (29.44) <0.001
CysC des-S 107/33/34/40 −486.92 (92.06) <0.0001 −375.06 (310.95) 0.24 −100.46 (213.44) 0.64 −281.68 (72.88) <0.001
Native CysC 107/33/34/40 −16.40 (4.03) <0.001 4.32 (11.60) 0.71 −4.86 (8.18) 0.56 −10.24 (3.86) 0.01
Linear regression with eGFR as the dependent variable and total CysC, CysC des-SSP, CysC des-S, native CysC concentrations as the independent variables adjusted
for age, sex and BMI. Type Ι error rate = 0.02 adjusted for multiple comparisons
N = number of subjects in combined sample (control + DM + CKD)
N1 = Control
N2 = DM
N3 = CKD
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proteoforms concentrations were also significantly
greater in the setting of urine microalbuminuria. The
association with eGFR was stronger with the truncated
proteoforms than native CysC and was only significant
in participants with both CKD and DM. These findings
highlight the importance of measuring truncated CysC
proteoforms.
Total CysC was shown previously to be a specific
predictor of eGFR [8, 10]. The lack of correlation of
CysC proteoforms with eGFR in the control and DM
groups was noteworthy. The MDRD Study equation to
estimate GFR is best in the lower ranges of GFR [18].
GFR estimates from the MDRD Study equation greater
than 60 mL/min/1.73 m2 underestimate measured GFR,
and may lead to misdiagnosis and misclassification of
CKD in individuals with mild renal insufficiency [19, 20].
This limitation highlights the need of new CKD bio-
markers to capture early disease risk.
The mechanism of CysC truncations is not well under-
stood. The N-terminal residues of CysC were found toTable 5 Distribution of CysC proteoforms concentrations by albumi
N1/N2/N3 Normoalbuminuria
Native CysC (mg/L) 78/18/8 1.18 (0.51)
CysC des-S (mg/L) 78/18/8 0.041 (0.025)
CysC des-SSP (mg/L) 78/18/8 0.061 (0.047)
Mean (SD). Statistical significance defined with a p < 0.02. Groups compared with A
N1 = number of participants with normoalbuminuria
N2 = number of participants with microalbuminuria
N3 = number of participants with macroalbuminuria
aNative CysC
In macro vs. normoalbuminuria, p = 0.03
In macro vs. microalbuminuria, p = 0.8
In micro vs. normoalbuminuria, p = 0.03
bCysC des-S
In macro vs. normoalbuminuria, p = 0.05
In macro vs. microalbuminuria, p = 0.6
In micro vs. normoalbuminuria, p = 0.2
cCysC des-SSP
In macro vs. normoalbuminuria, p = 0.16
In macro vs. microalbuminuria, p = 0.99
In micro vs. normoalbuminuria, p = 0.02be important in determining the specificity of CysC with
cysteine proteinases [21]. It is known that leucocyte
elastase cleaves the Val10-Gly11 bond of cystatin C [22],
and cathepsin L cleaves the Gly11-Gly12 bond [23]. The
NMR structure of CysC shows that the N-terminal
fragment is unstructured and highly mobile [24]. The N-
terminus also contains the binding site for the cysteine
proteinases, and when removed through truncations, the
inhibition of proteinases is drastically reduced due to the
decreased affinity [21]. Therefore, it is likely that the
truncated des-S and des-SSP CysC proteoforms exhibit
reduced biological activity. Our data suggest that CysC
truncations can be markers of disease severity and used
as more specific measures of CKD than native CysC.
Therefore, evaluating changes in CysC truncations can
be a useful indicator of CKD progression.
The strength of this study lies in the simple MS-based
quantitative proteomics approach to assess CysC proteo-
forms, that is both high throughput and accurate. There
are some limitations to this study. MSIA was not able to
resolve signals from hydroxylated CysC (3Pr-OH) fromnuria groups
Microalbuminuria Macroalbuminuria p-value
1.56 (0.57) 1.70 (0.68) 0.02a
0.053 (0.030) 0.06 (0.019) 0.003b
0.096(0.071) 0.096 (0.048) 0.01c
NOVA followed by Tukey’s pairwise comparisons
Yassine et al. Proteome Science  (2016) 14:7 Page 8 of 8native CysC at baseline due to the small mass difference
among these proteoforms. A previous study demon-
strated CysC and truncations levels can fluctuate daily
by as much as 2 fold within the normal range [13],
which could bias our findings given our limited sample
size. Another limitation is the small sample size of the
subgroups with advanced CKD, stages 4 and 5. Our find-
ings warrant an investigation of Cystatin C proteoforms
in larger CKD studies with measured GFR to discrimin-
ate the capacity of these proteoforms versus eGFR in
predicting GFR decline.
Conclusions
We conclude that CysC proteoforms are increased in
patients with DM and CKD. Truncated proteoforms,
independent of native CysC, associate with eGFR. Future
studies are needed to further investigate the relation
between CysC proteoforms in early renal disease and for
their utility as biomarkers of CKD progression.
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